Aletekitug

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

8 competitors in Colitis, Ulcerative

#DrugCompanyPhaseTrials

1

Tremfya

Johnson & Johnson

Phase 3

42

Omvoh

Eli Lilly

Phase 2

13

Velsipity

Pfizer

Phase 2

34

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

15

Zeposia

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

16

Aletekitug

GSK

Phase 1

2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Colitis, Ulcerative2 trials

A Phase 1b, Non-Randomized, Open-Label, Repeat-Dose, Single Center Study Utilizing a Master Protocol to Investigate the Safety and Tolerability of Multiple Study Interventions in Advanced Therapy Naïve Participants With Moderate to Severe Ulcerative Colitis

Recruiting·GSK·Phase 1·NCT07747467·8 enrolled

A Phase 1b, Non-Randomized, Open-Label, Repeat-Dose, Single Center Study to Investigate the Safety and Tolerability of Aletekitug in Advanced Therapy Naïve Participants With Moderate to Severe Ulcerative Colitis

Not yet recruiting·GSK·Phase 1·NCT07747480·16 enrolled

Details

Drug Info

Related News